Telitacicept Receives First-Ever Approval for Sjögren's Disease in China, Validating VOR's Global Program
VOR has more than doubled off its 52-week low of $3.626.
Summary
China's NMPA has approved telitacicept for Sjögren's disease, marking the first-ever regulatory approval for this indication globally and the fifth overall for the drug. While partner RemeGen holds commercial rights in China, Vor Biopharma holds exclusive rights outside Greater China and is advancing telitacicept in global Phase 3 trials for Sjögren's disease. This approval provides significant clinical validation for VOR's ongoing development program, de-risking a drug targeting a common autoimmune condition with no current systemic disease-modifying therapies. This positive news follows recent reports of a large net loss and insider selling.
At the time of this announcement, VOR was trading at $13.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $713.1M. The 52-week trading range was $3.63 to $65.80. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.